There are currently 973 clinical trials in Birmingham, Alabama looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Alabama at Birmingham, University of Alabama, University of Alabama at Birmingham Cancer Center and University of Alabama-Birmingham. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
NCT06609226
Recruiting
Etavopivat is a new medicine under development for treating blood disorders like sickle cell disease and thalassaemia. Sickle cell disease and thalassaemia are inherited blood disorders that affect haemoglobin. Haemoglobin is the protein that carries oxygen through the body. This study is looking into how safe treatment with etavopivat is and how well it works over a long period of time. The study will last for up to 264 weeks, but it will end earlier if etavopivat is approved in the participant... Read More
Gender:
ALL
Ages:
All
Trial Updated:
05/19/2025
Locations: Univ of Alabama Birmingham, Birmingham, Alabama
Conditions: Sickle Cell Disease, Thalassemia
Register for Updates
Pompe Disease Registry Protocol
NCT00231400
Recruiting
The Pompe Registry is a global, multicenter, international, longitudinal, observational, and voluntary program for patients with Pompe disease, designed to track the disease's natural history and outcomes in patients, both treated and not. Data from the Registry are also used to fulfill various global regulatory commitments, to support product development/reimbursement, and for other research and non-research related purposes. The objectives of the Registry are: * To enhance understanding of t... Read More
Gender:
ALL
Ages:
All
Trial Updated:
05/19/2025
Locations: University Alabama at Birmingham- Site Number : 840106, Birmingham, Alabama
Conditions: Glycogen Storage Disease Type II, Pompe Disease
Register for Updates
Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)
NCT06079671
Recruiting
This is a phase III, randomized, double-blind, placebo-controlled, multi-center, global study to explore the efficacy and safety of volrustomig in women with high-risk LACC (FIGO 2018 stage IIIA to IVA cervical cancer) who have not progressed following platinum-based CCRT.
Gender:
FEMALE
Ages:
15 years and above
Trial Updated:
05/19/2025
Locations: Research Site, Birmingham, Alabama
Conditions: Locally Advanced Cervical Cancer
Register for Updates
A Research Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
NCT06612268
Recruiting
This study is conducted to confirm whether etavopivat works well at reducing the number of Vaso-occlusive crisis VOCs (sickle cell pain crises) caused by obstructions in blood vessels in adults and adolescents living with sickle cell disease. The study will also evaluate how well etavopivat can reduce the damage to different organs, improve your exercise tolerance and reduce fatigue in people with sickle cell disease.The participants will either get etavopivat or placebo. Which treatment the par... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
05/19/2025
Locations: Uni of Alabama at Birmingham, Birmingham, Alabama
Conditions: Sickle Cell Disease
Register for Updates
Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors
NCT06635785
Recruiting
BIPAVE-001 is a Phase 1-2 study for evaluating the safety, pharmacokinetics (PK), and efficacy of AI-081 in solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Advanced Solid Tumor
Register for Updates
A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti--IL-33 mAb) in Participants With Chronic Rhinosinusitis Without Nasal Polyps
NCT06691113
Recruiting
ACT18421 is a multinational, randomized, double-blind, placebo-controlled, parallel-group, Phase 2 study with 3 treatment groups. The purpose of the study is to evaluate the efficacy, safety and tolerability of 2 dosing regimens of itepekimab compared to placebo in male and female participants with chronic rhinosinusitis without nasal polyps (CRSsNP) aged 18 years of age and older. Study details include: * The study duration (4-week screening, 24--week intervention, 20--week safety followup) w... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: Alabama Allergy & Asthma Center - Birmingham - Brookwood Boulevard- Site Number : 8400006, Birmingham, Alabama
Conditions: Chronic Rhinosinusitis Without Nasal Polyps
Register for Updates
RECOVER-ENERGIZE Platform Protocol
NCT06404047
Recruiting
This is a platform protocol designed to be flexible so that it is suitable for a range of interventions and settings within diverse health care systems and community settings with incorporation into clinical COVID-19 management programs and treatment plans if results achieve key study outcomes. This protocol is a prospective, multi-center, multi-arm, randomized, controlled platform trial evaluating interventions to address and improve exercise intolerance and post-exertional malaise (PEM) as ma... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Long COVID, Long Covid19, Long Covid-19
Register for Updates
Edwards PASCAL CLASP IID/IIF Pivotal Clinical Trial
NCT03706833
Recruiting
To establish the safety and effectiveness of the Edwards PASCAL Transcatheter Valve Repair System in patients with degenerative mitral regurgitation (DMR) who have been determined to be at prohibitive risk for mitral valve surgery by the Heart Team, and in patients with functional mitral regurgitation (FMR) on guideline directed medical therapy (GDMT)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: The University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Degenerative Mitral Valve Disease, Mitral Regurgitation, Mitral Insufficiency, Functional Mitral Regurgitation
Register for Updates
Survival and Dialysis Independency in Highly Sensitized Patients After Desensitization With Imlifidase and Tx of Kidneys
NCT05714514
Recruiting
The goal of this follow-up study is to learn about long-term patient survival and graft function in highly sensitized patients who have received desensitization treatment with imlifidase or standard of care (SoC) in order to enable kidney transplantation in clinical study ConfIdeS (20-HMedIdeS-17, NCT04935177).
Gender:
ALL
Ages:
All
Trial Updated:
05/19/2025
Locations: University of Alabama at Birmingham (UAB) Hospital, Birmingham, Alabama
Conditions: Kidney Transplantation in Highly Sensitized Patients
Register for Updates
5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder
NCT05452772
Recruiting
This is a multi-site, double-blind, randomized clinical trial of the 5-HT2A receptor agonist psilocybin for smoking cessation. Four sites with experience in conducting psilocybin research will be involved in this trial: Johns Hopkins University (JHU), the University of Alabama at Birmingham (UAB), New York University (NYU), and Sheppard Pratt (SP). The proposed study will treat 66 participants (22 at each site), randomized to receive either: 1) oral psilocybin (30 mg in session 1 and either 30 m... Read More
Gender:
ALL
Ages:
21 years and above
Trial Updated:
05/19/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Tobacco Use Disorder
Register for Updates
Real-world Clinical Outcomes of the MITRIS RESILIA Mitral Valve
NCT05526560
Recruiting
Collect real-world data on acute and long-term safety and performance of the MITRIS RESILIA Mitral Valve, Model 11400M, in subjects requiring replacement of their native or prosthetic mitral valve with or without concomitant procedures.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: University of Alabama Hospital, Birmingham, Alabama
Conditions: Mitral Stenosis, Mitral Valve Insufficiency
Register for Updates
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-refractory Multiple Myeloma (QUINTESSENTIAL-2)
NCT06615479
Recruiting
The purpose of this study is to compare the efficacy and safety of BMS-986393 versus standard regimens in adult participants with Relapsed or Refractory and Lanalidomide-refractory Multiple Myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: Local Institution - 0071, Birmingham, Alabama
Conditions: Relapsed or Refractory Multiple Myeloma (RRMM)
Register for Updates